Emerging studies suggest this peptide, a dual activator targeting both incretin and GIP , could represent a notable advancement for body loss . Initial human trials have shown impressive losses in body mass , possibly retatrutide review outperforming other obesity medications . Despite this, additional assessment is needed to thoroughly determine i